Alvotech Investor Relations Material

Alvotech is a biopharmaceutical company focused on developing and manufacturing high-quality biosimilar medicines. The company aims to improve patient health by increasing access to affordable biologic treatments. Alvotech specializes in biosimilars targeting therapeutic areas such as autoimmune diseases, eye disorders, osteoporosis, respiratory diseases, and cancer. Their pipeline includes a range of monoclonal antibodies aimed at treating various conditions within these areas. The company maintains a vertically integrated approach from cell line development through fill and finish manufacturing, which enhances their control, scale, and speed in bringing products to market. The company is headquartered in Luxembourg, and its shares are listed on the NASDAQ.